web analytics

Next-Generation Minimally Invasive Optoelectronic Implants For Chronic Disease Management

Published:
Lead Inventor: Bozhi Tian
Print or Save to PDF

SUMMARY

The platform delivers ultra-low intensity, wireless, fully implantable photostimulation for deep tissue targets (nerves, heart, diaphragm). It spatially separates light harvesting from bioelectrical stimulation, enabling minimally invasive, leadless, genetic-modification-free interventions.

The Unmet Need: Fully implantable, wireless, and low-power devices that can deliver effective neuromodulation to deep tissues without high-intensity light, external tethers, or genetic modification

  • Implantable bioelectronic devices hold great promise for treating conditions such as obstructive and central sleep apnea, cardiac arrhythmia, and chronic pain. However, current technologies are constrained by the need for invasive leads, high-intensity power sources, or genetic modification, restricting patient eligibility and long-term adoption. Light-based approaches (such as optogenetics or monolithic photoelectrodes) typically require high optical power to penetrate tissue, often exceeding safety standards and complicating device design.

  • Wireless and batteryless solutions that decouple the sites of light absorption and electrical stimulation can, in principle, enable a new class of fully implantable therapeutics. Recent advances in material science and microfabrication enable high-capacitance, low-impedance supercapacitor biointerfaces, but translational barriers have persisted.

The Proposed Solution: A wireless, fully implantable system that spatially separates light harvesting from electrical stimulation, achieving safe, ultra-low power deep tissue neuromodulation or pacing without leads, genetic modification, or external tethers<

  • The faculty inventor developed a heterospatial optoelectronic supercapacitor system that enables minimally invasive, leadless photostimulation of deep biological tissues. The technology spatially separates the light-absorbing photoanode (placed near the skin for maximal light capture) and the charge-injecting cathode (implanted near biological targets such as nerves or myocardium) and connects them via an insulated conductor. Advanced material engineering—specifically the pairing of porous silicon/TiO₂/TiN photoanodes with dealloyed nanoporous platinum cathodes—yields unprecedented charge storage and delivery at ultra-low light intensities (0.007–0.018 mW/mm²), well below safety standards and ambient light levels.

ADVANTAGES

ADVANTAGES

  • Closed-skin, fully wireless, and programmable operation

  • Leadless, batteryless, and external-fiber-free implantation

  • Ultra-low power trigger (orders of magnitude lower light intensity than alternatives)

  • Compatible with Bluetooth-enabled wearable light sources

APPLICATIONS

  • Sleep apnea neurostimulators (hypoglossal/phrenic nerve)

  • Wireless cardiac pacing and arrhythmia management

  • Peripheral nerve stimulation for pain and neurologic disease

  • Expandable to closed-loop modulation, chronic monitoring, or combination bioelectronic therapies

  • Validated across small and large animal models, achieving functional neuromodulation (e.g., hypoglossal nerve stimulation for OSA, cardiac pacing, and diaphragmatic stimulation for CSA) with clinical scalability.